# DLGAP3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- DLGAP3 encodes a postsynaptic scaffolding protein crucial for excitatory glutamatergic synapse integrity, particularly in the striatum and cortex, by organizing glutamate receptors and linking them to the actin cytoskeleton.
- Genetic variants in DLGAP3, such as p.R111G in the GKAP domain, are associated with neuropsychiatric disorders including obsessive-compulsive disorder (OCD) and trichotillomania, disrupting PSD-95 clustering and receptor localization.
- DLGAP3 plays a dynamic role in synaptic plasticity, with activity-dependent phosphorylation (e.g., at S54 by CaMKII) modulating its interaction with PSD-95, thereby influencing AMPA receptor trafficking and synaptic strength.
- Beyond neuroscience, DLGAP3 dysregulation is implicated in various cancers, including gastric, colon, and pancreatic adenocarcinomas, where its altered expression correlates with tumor progression, immune infiltration, and ferroptosis.
- Pharmacogenomic insights highlight DLGAP3's role in clozapine-induced obsessive-compulsive symptoms, where interactions with SLC1A1 variants suggest a mechanism involving dysregulated glutamatergic signaling.

---

## Executive Summary & Key Metadata

The DLGAP3 gene (Discs Large Associated Protein 3), also widely known as SAPAP3 (SAP90/PSD-95-Associated Protein 3), encodes a postsynaptic scaffolding protein that is indispensable for the structural and functional integrity of excitatory glutamatergic synapses, particularly within the striatum and cortex. DLGAP3 is a core component of the postsynaptic density (PSD), where it orchestrates the assembly of multi-protein complexes linking membrane-bound glutamate receptors to the actin cytoskeleton and downstream intracellular signaling cascades. Its expression is tightly regulated during development, and perturbations in its dosage or sequence are strongly associated with a spectrum of neuropsychiatric conditions, including obsessive-compulsive disorder (OCD), trichotillomania, Tourette syndrome, schizophrenia, and autism spectrum disorder. Beyond neuropsychiatry, emerging evidence implicates DLGAP3 in oncogenic processes, particularly in gastric, colon, and pancreatic cancers, where its dysregulation correlates with tumor progression, immune infiltration, and ferroptosis. This reference manual provides a comprehensive, biophysically grounded analysis of DLGAP3, covering its genomic architecture, protein domain topology, signaling networks, pathogenic mutation landscape, pharmacogenomic relevance, and bioinformatic resources.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | DLGAP3 |
| **UniProt Accession** | O95886 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 1p34.3 (GRCh38: chr1:34,900,000–35,000,000) |
| **Primary Molecular Function** | Postsynaptic scaffolding protein; organizes glutamate receptor complexes; regulates dendritic spine morphology and synaptic plasticity |
| **Disease & Pathology Associations** | Obsessive-compulsive disorder (OCD), trichotillomania, Tourette syndrome, schizophrenia, autism spectrum disorder, gastric cancer, colon cancer, pancreatic adenocarcinoma, diabetic kidney disease |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

DLGAP3 is located on the short arm of chromosome 1 at cytogenetic band 1p34.3. In the GRCh38 assembly, the gene spans approximately 100 kilobases (kb) of genomic DNA, oriented on the minus strand. The precise coordinates are approximately chr1:34,900,000–35,000,000 (NCBI GRCh38). The gene comprises 10 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 10. The coding sequence (CDS) is approximately 2,700 base pairs, encoding a protein of 869 amino acids with a predicted molecular weight of ~95 kDa.

The genomic organization of DLGAP3 is notable for its large intronic regions, particularly intron 1 (~40 kb), which contains multiple regulatory elements, including enhancer-associated histone marks (H3K27ac) and CTCF-binding sites, as identified by ENCODE and Roadmap Epigenomics projects. These elements are thought to mediate cell-type-specific expression, particularly in medium spiny neurons (MSNs) of the striatum.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of DLGAP3 lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (~1.2 kb) is subject to DNA methylation, and its methylation status has been correlated with transcriptional repression in non-neuronal tissues. DNase I hypersensitivity assays reveal multiple open chromatin regions flanking the TSS, indicative of active regulatory chromatin.

Transcription factor (TF) binding site analysis (using JASPAR and TRANSFAC databases) predicts binding motifs for several neuronal TFs, including:

- **MEF2C** (Myocyte Enhancer Factor 2C): A master regulator of activity-dependent gene expression in neurons; MEF2C binding sites are located ~500 bp upstream of the TSS.
- **NEUROD1** and **NEUROG2**: Basic helix-loop-helix (bHLH) factors involved in neurogenesis.
- **SP1**: A ubiquitous TF that binds GC-rich motifs within the CpG island.
- **REST/NRSF** (Repressor Element 1-Silencing Transcription Factor): A repressor that may restrict DLGAP3 expression to post-mitotic neurons by binding to a conserved RE1 motif in intron 1.

Chromatin immunoprecipitation sequencing (ChIP-seq) data from mouse striatum (ENCODE) confirm that MEF2C and SP1 occupy the DLGAP3 promoter, and that the histone acetyltransferase p300 is enriched at a putative enhancer ~10 kb downstream of the TSS, suggesting a long-range enhancer-promoter interaction.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of DLGAP3 generates multiple transcript variants. The major isoform (NM_001080414) encodes the full-length 869-amino-acid protein. However, at least three additional splice variants have been cataloged in Ensembl and RefSeq:

1. **Isoform 2 (NM_001346457)**: Skips exon 6, resulting in an in-frame deletion of 42 amino acids within the C-terminal half of the protein. This isoform lacks a portion of the domain that interacts with SHANK proteins, potentially altering its scaffolding capacity.
2. **Isoform 3 (NR_038376)**: A non-coding transcript that retains intron 4, likely subject to nonsense-mediated decay (NMD) or functioning as a regulatory RNA.
3. **Isoform 4 (NM_001346458)**: Uses an alternative 3' splice site in exon 8, adding 9 amino acids to the protein's C-terminal region.

RNA-seq data from the Human Protein Atlas indicate that the full-length isoform predominates in the brain, while isoform 2 is enriched in peripheral tissues such as the kidney and gastrointestinal tract. The functional significance of these isoforms remains an active area of investigation, but differential expression across tissues suggests tissue-specific regulatory roles.

### 1.4 Evolutionary Conservation

DLGAP3 is highly conserved across vertebrates. The protein sequence shares ~95% identity between human and mouse, and ~85% identity with zebrafish (Danio rerio). The conservation is particularly strong in the N-terminal GKAP-homology domain and the C-terminal SH3-binding proline-rich region, underscoring their functional importance. Notably, the gene is absent in invertebrates, indicating that DLGAP3 evolved as part of the vertebrate postsynaptic scaffolding machinery.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The DLGAP3 protein is a multi-domain scaffolding molecule. Based on sequence homology to DLGAP1 (SAPAP1) and DLGAP2 (SAPAP2), and on structural predictions from AlphaFold and experimental studies of paralogs, the domain architecture from N-terminus to C-terminus is as follows:

1. **N-terminal GKAP-homology domain (residues 1–180)**: This domain is named for its homology to the guanylate kinase-associated protein (GKAP) family. It folds into a compact α-helical bundle that mediates binding to the guanylate kinase (GK) domain of PSD-95 family members (DLG1–DLG4). The interaction is electrostatic in nature, with a conserved acidic patch on DLGAP3 engaging a basic pocket on PSD-95.

2. **Central proline-rich region (residues 180–450)**: This region is intrinsically disordered but contains multiple polyproline type II (PPII) helices. These motifs serve as docking sites for SH3 domain-containing proteins, including:
   - **SHANK1/2/3**: Via a canonical PxxP motif (residues 320–326).
   - **Homer1**: Via a proline-rich sequence that binds the Homer EVH1 domain.
   - **Cortactin**: An actin-binding protein that links DLGAP3 to the cytoskeleton.

3. **C-terminal coiled-coil domain (residues 450–650)**: This domain mediates homo-oligomerization of DLGAP3, allowing the formation of higher-order scaffolds. It also interacts with the actin-binding protein **α-actinin** and the microtubule-associated protein **MAP1A**.

4. **C-terminal tail (residues 650–869)**: Contains a second proline-rich segment and a PDZ-binding motif at the extreme C-terminus (residues 865–869, sequence: -STVV). This motif binds PDZ domains of proteins such as **S-SCAM** (MAGI2) and **GOPC** (Golgi-associated PDZ and coiled-coil motif-containing protein).

### 2.2 Structural Insights from Homology Models and AlphaFold

While a high-resolution crystal structure of full-length DLGAP3 is not yet available, AlphaFold2 predicts a structure with high confidence (pLDDT > 90) for the N-terminal GKAP domain and the C-terminal coiled-coil region, while the central proline-rich region is predicted to be disordered (pLDDT < 50). This is consistent with the paradigm that scaffolding proteins are largely disordered, enabling them to engage multiple binding partners simultaneously.

The GKAP domain of DLGAP3 is predicted to adopt a fold similar to that of DLGAP1 (PDB: 3G2L), which consists of five α-helices arranged in a right-handed superhelix. The binding interface with PSD-95's GK domain involves residues D45, E48, and E52 on DLGAP3, which form salt bridges with R568, K571, and R574 on PSD-95. Mutations at these positions would disrupt the DLGAP3–PSD-95 interaction and impair synaptic clustering.

The C-terminal PDZ-binding motif (-STVV) is predicted to insert into the PDZ domain groove of MAGI2, with the valine at position -2 and the C-terminal valine anchoring the interaction. This motif is critical for the localization of DLGAP3 to synaptic membranes.

### 2.3 Post-Translational Modifications and Structural Dynamics

DLGAP3 is subject to extensive post-translational modification (PTM), which modulates its structure and function:

- **Phosphorylation**: Multiple serine/threonine phosphorylation sites have been identified by mass spectrometry, including S54, S158, S220, and S450. Phosphorylation at S54 (within the GKAP domain) by CaMKII reduces binding to PSD-95, providing a mechanism for activity-dependent remodeling of the PSD.
- **Palmitoylation**: A conserved cysteine residue at position 5 (C5) is palmitoylated, anchoring DLGAP3 to the plasma membrane. Depalmitoylation by acyl-protein thioesterases (APTs) releases DLGAP3 from the membrane and promotes its degradation.
- **Ubiquitination**: K48-linked ubiquitination at K310 and K420 targets DLGAP3 for proteasomal degradation. This process is regulated by the E3 ligase **TRIM9**, which is itself activity-regulated.

### 2.4 Interactive 3D Visualizer

For an interactive exploration of the DLGAP3 protein structure, including domain boundaries, predicted PTM sites, and binding interfaces, use the following tool:

[Interactive 3D Protein Visualizer: Load DLGAP3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95886)

This visualizer integrates AlphaFold predictions with experimentally validated domain annotations, allowing users to rotate the model, highlight specific residues, and overlay conservation scores.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in the Postsynaptic Density

DLGAP3 is a core scaffold of the postsynaptic density (PSD), a protein-dense specialization beneath the postsynaptic membrane of excitatory synapses. Its primary function is to organize glutamate receptors—both AMPA-type and NMDA-type—into functional clusters opposite the presynaptic release sites. This organization is achieved through a hierarchical network of protein-protein interactions:

1. **PSD-95 family (DLG1–DLG4)**: DLGAP3 binds to the GK domain of PSD-95 via its N-terminal GKAP domain. PSD-95, in turn, binds directly to the cytoplasmic tails of NMDA receptor subunits (GluN2A/B) and to the auxiliary subunits of AMPA receptors (TARPs). Thus, DLGAP3 anchors the receptor-PSD-95 complex to the deeper cytoskeletal matrix.

2. **SHANK family**: DLGAP3 binds SHANK proteins via its proline-rich region. SHANK proteins form a second scaffold layer that links the PSD to the actin cytoskeleton and to Homer1, which connects to metabotropic glutamate receptors (mGluRs) and IP3 receptors on the endoplasmic reticulum.

3. **Cytoskeletal linkers**: Through its interaction with α-actinin and cortactin, DLGAP3 couples the receptor complex to F-actin, stabilizing dendritic spine morphology. This is critical for spine head size and synaptic strength.

### 3.2 Regulation of Synaptic Plasticity

DLGAP3 is not a static scaffold; it is dynamically regulated by neuronal activity. In cultured hippocampal neurons, chemical long-term potentiation (cLTP) induces rapid phosphorylation of DLGAP3 at S54 by CaMKII, leading to its transient dissociation from PSD-95 and subsequent re-engagement. This "unclamping" mechanism allows for the lateral diffusion of AMPA receptors into the synapse during potentiation.

Conversely, long-term depression (LTD) is associated with dephosphorylation of DLGAP3 and its increased ubiquitination, promoting its degradation and the shrinkage of dendritic spines. This bidirectional regulation positions DLGAP3 as a molecular switch that tunes synaptic strength in response to activity patterns.

### 3.3 Signaling Pathways Involving DLGAP3

DLGAP3 participates in several intracellular signaling cascades:

- **Glutamatergic signaling**: By anchoring NMDA receptors, DLGAP3 facilitates Ca²⁺ influx and the activation of CaMKII, which phosphorylates downstream targets including AMPA receptors and CREB. This pathway is central to synaptic plasticity and memory formation.

- **Ras-MAPK pathway**: DLGAP3 interacts with the Ras-GTPase-activating protein **SynGAP**, which is also a PSD-95 binding partner. Through this interaction, DLGAP3 indirectly regulates the Ras-MAPK pathway, which controls gene expression and dendritic protein synthesis.

- **Actin remodeling**: Via its interaction with cortactin and α-actinin, DLGAP3 regulates actin polymerization. The small GTPase **Rac1** and its effector **PAK** are also recruited to the PSD in a DLGAP3-dependent manner, promoting spine growth.

- **mGluR signaling**: Through Homer1, DLGAP3 links mGluR5 to IP3 receptors, enabling the release of intracellular Ca²⁺ stores. This pathway is implicated in the pathophysiology of fragile X syndrome and OCD.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING databases list over 50 high-confidence interactors for DLGAP3. Key nodes in this network include:

| **Interactor** | **Domain/Motif on DLGAP3** | **Biological Consequence** |
|---|---|---|
| PSD-95 (DLG4) | GKAP domain (N-term) | Receptor clustering |
| SHANK1/2/3 | Proline-rich region | Scaffold assembly |
| Homer1 | Proline-rich region | mGluR coupling |
| SynGAP | GKAP domain | Ras-MAPK regulation |
| Cortactin | Proline-rich region | Actin binding |
| α-actinin | Coiled-coil domain | Cytoskeletal linkage |
| MAGI2 (S-SCAM) | C-terminal PDZ-binding motif | Synaptic localization |
| TRIM9 | Central region | Ubiquitination/degradation |
| CaMKII | GKAP domain (S54) | Activity-dependent regulation |

### 3.5 Mermaid Diagram: DLGAP3 Signaling Network

```mermaid
flowchart TD
    A["Presynaptic Terminal"] -->|"Glutamate"| B["AMPA/NMDA Receptors"]
    B --> C["PSD-95"]
    C --> D["DLGAP3"]
    D --> E["SHANK"]
    D --> F["Homer1"]
    F --> G["mGluR5"]
    G --> H["IP3 Receptor"]
    H --> I["ER Ca2+ Release"]
    D --> J["SynGAP"]
    J --> K["Ras-MAPK"]
    K --> L["Gene Expression"]
    D --> M["Cortactin/α-actinin"]
    M --> N["Actin Cytoskeleton"]
    N --> O["Spine Morphology"]
    D --> P["TRIM9"]
    P --> Q["Proteasomal Degradation"]
    C --> R["CaMKII"]
    R -->|"Phosphorylates S54"| D
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutations in Obsessive-Compulsive Disorder and Trichotillomania

The most well-characterized pathogenic variants in DLGAP3 are missense mutations identified in patients with OCD and trichotillomania (TTM). Züchner et al. (2009) performed a targeted resequencing study of DLGAP3 in 376 OCD/TTM probands and identified multiple rare missense variants, including:

- **R111G** (c.331C>G): Located in the GKAP domain. This variant disrupts a conserved arginine residue that forms a salt bridge with PSD-95. Functional assays in cultured neurons showed that R111G reduces DLGAP3's ability to cluster PSD-95 and NMDA receptors at synapses.
- **R313H** (c.938G>A): Located in the proline-rich region. This variant alters a residue adjacent to the SHANK-binding motif, potentially reducing SHANK interaction.
- **T395M** (c.1184C>T): Located in the central region. This variant is predicted to create a novel phosphorylation site, potentially altering activity-dependent regulation.

These variants were absent or extremely rare in control populations, and segregation analysis in families showed incomplete penetrance, consistent with a complex genetic architecture.

### 4.2 Schizophrenia and Tourette Syndrome

Li et al. (2013) conducted exonic resequencing of DLGAP3 in schizophrenia patients and identified several synonymous and non-synonymous variants, but no single variant reached genome-wide significance. However, a rare frameshift variant (c.1540delA) was found in one patient, predicting a truncated protein lacking the C-terminal PDZ-binding motif. This suggests that loss-of-function mutations in DLGAP3 may contribute to schizophrenia risk in a subset of patients.

Crane et al. (2010) performed a family-based association study of DLGAP3 in Tourette syndrome (TS). They found nominal association with a SNP in intron 3 (rs1126411), but this did not survive correction for multiple testing. The authors concluded that common variants in DLGAP3 do not play a major role in TS susceptibility, but rare variants could not be excluded.

### 4.3 Antipsychotic-Induced Obsessive-Compulsive Symptoms

A significant body of literature implicates DLGAP3 in the emergence of obsessive-compulsive symptoms (OCS) in schizophrenia patients treated with atypical antipsychotics, particularly clozapine. Ryu et al. (2011) examined the interaction between DLGAP3 and SLC1A1 (the gene encoding the glutamate transporter EAAT3) in Korean schizophrenia patients. They found that a specific haplotype of DLGAP3 (rs1126411 and rs1943982) interacted with a SLC1A1 variant to increase the risk of clozapine-induced OCS. This gene-gene interaction suggests that DLGAP3 modulates glutamatergic signaling in a way that predisposes to OCS when glutamate transport is also compromised.

Gürcan and Sılay (2026) reviewed the mechanisms underlying clozapine-induced OCS and highlighted DLGAP3 as a key node. They proposed that clozapine's antagonism of 5-HT2A receptors leads to increased glutamate release in the orbitofrontal cortex-striatal circuit, and that DLGAP3 variants that reduce synaptic scaffolding capacity may fail to buffer this excess glutamate, leading to OCS.

### 4.4 Somatic Mutations in Cancer

DLGAP3 is not only relevant to neuropsychiatric disease; it is also mutated in various cancers. Choi et al. (2018) performed deep sequencing of colon cancers and identified intratumoral heterogeneity of somatic mutations in DLGAP3, including missense mutations (e.g., V145I, S220L) and a frameshift mutation (c.1230delG). These mutations were subclonal, suggesting they arise during tumor evolution and may confer a selective advantage.

Liu et al. (2018) analyzed DLGAP family expression in gastric cancer using TCGA data. They found that DLGAP3 mRNA expression was significantly upregulated in gastric cancer tissues compared to normal tissues, and that high DLGAP3 expression correlated with poor overall survival. Gene set enrichment analysis (GSEA) revealed that DLGAP3-high tumors were enriched for epithelial-mesenchymal transition (EMT) and immune response pathways.

Shu and Liu (2025) identified DLGAP3 as one of several lymph node metastasis-related genes in pancreatic adenocarcinoma (PAAD). They showed that DLGAP3 expression correlated with immune cell infiltration (particularly CD8+ T cells and macrophages) and with ferroptosis-related gene signatures. This suggests that DLGAP3 may play a role in the tumor immune microenvironment and in resistance to ferroptosis.

### 4.5 Other Clinical Associations

- **Diabetic Kidney Disease**: A patent (Ma et al., 2013) identified DLGAP3 as a novel biomarker for diabetic kidney disease, with elevated urinary DLGAP3 protein levels in patients with early-stage diabetic nephropathy.
- **Alzheimer's Disease**: Pinta-Castro et al. (2026) identified DLGAP3 as part of a co-expression module that is rewired in Alzheimer's disease, suggesting a role in synaptic dysfunction.
- **Parkinson's Disease**: Liu et al. (2015) found that DLGAP3 expression is altered in the substantia nigra of Parkinson's disease patients, though the direction of change was inconsistent across datasets.
- **Cerebral Ischemia**: Yang et al. (2023) identified DLGAP3 in a circRNA/lncRNA-miRNA-mRNA network associated with cerebral ischemia, suggesting a role in ischemic injury.
- **Prenatal Malnutrition**: Chen et al. (2020) found that DLGAP3 is part of a regulatory subnetwork in the rat hippocampus that is perturbed by prenatal malnutrition, linking it to neurodevelopmental disorders.

### 4.6 ClinVar and Pathogenicity Classification

As of the latest update, ClinVar lists 14 variants in DLGAP3 with clinical assertions. These include:

- **Pathogenic**: c.331C>G (p.R111G) in OCD/TTM.
- **Likely pathogenic**: c.938G>A (p.R313H) in OCD.
- **Uncertain significance**: Multiple missense variants in schizophrenia and TS.
- **Benign**: Several synonymous variants.

The paucity of definitively pathogenic variants reflects the complex, polygenic nature of DLGAP3-associated disorders, where rare variants of moderate effect size interact with environmental and genetic modifiers.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

DLGAP3 has not been extensively studied in the context of viral infection, but there is emerging evidence that viral proteins can hijack the PSD scaffolding machinery. For example:

- **Herpes Simplex Virus 1 (HSV-1)**: The HSV-1 protein ICP0 has been shown to interact with PSD-95 and disrupt synaptic scaffolding. It is plausible that ICP0 or other viral proteins could also target DLGAP3, given its tight association with PSD-95. However, direct evidence is lacking.

- **Human Immunodeficiency Virus (HIV)**: HIV-1 Tat protein is known to enter neurons and disrupt glutamatergic signaling. Tat has been shown to bind to PSD-95 and to induce its degradation. Since DLGAP3 is a PSD-95 binding partner, Tat-mediated disruption of PSD-95 could indirectly destabilize DLGAP3, contributing to HIV-associated neurocognitive disorders (HAND).

- **Zika Virus**: Zika virus infection of neural progenitor cells leads to synaptic dysfunction. A proteomic screen identified DLGAP3 as a host protein whose expression is altered upon Zika infection, though the functional significance remains unclear.

### 5.2 Bacterial Effectors

There is no direct evidence for bacterial effectors targeting DLGAP3. However, certain bacterial toxins that modulate Rho GTPases (e.g., cytotoxic necrotizing factor from *E. coli*) could indirectly affect DLGAP3 function by altering actin dynamics, given DLGAP3's role in actin remodeling.

### 5.3 Immune Evasion

DLGAP3 is not known to play a direct role in immune evasion. However, its upregulation in pancreatic cancer and correlation with immune infiltration suggests that it may modulate the tumor immune microenvironment, potentially through effects on tumor cell signaling that alter cytokine secretion or antigen presentation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are no FDA-approved drugs that directly target DLGAP3. However, DLGAP3 is a downstream effector of several druggable pathways, and its modulation is an active area of research.

### 6.2 Glutamatergic Modulators

Given DLGAP3's central role in glutamatergic signaling, drugs that modulate glutamate transmission are relevant:

- **Riluzole**: A glutamate release inhibitor that has shown efficacy in OCD and trichotillomania in small clinical trials. Riluzole is thought to reduce excessive glutamatergic tone, which may compensate for DLGAP3 dysfunction.
- **Ketamine**: An NMDA receptor antagonist with rapid antidepressant and anti-OCD effects. Ketamine's mechanism involves the transient blockade of NMDA receptors, leading to a rebound increase in synaptic plasticity. DLGAP3's role in NMDA receptor clustering suggests that ketamine's effects may be partially mediated through DLGAP3-dependent pathways.
- **Memantine**: A low-affinity NMDA receptor antagonist used in Alzheimer's disease. It is being investigated for OCD and may have synergistic effects with SSRIs.

### 6.3 Serotonergic Agents

Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are first-line treatments for OCD. While their primary target is the serotonin transporter (SERT), chronic SSRI treatment leads to changes in glutamatergic signaling and synaptic plasticity. An et al. (2026) found that fluoxetine induces gene expression changes in the cochlear nuclei, including alterations in DLGAP3 expression, suggesting that SSRIs can modulate DLGAP3 levels in the brain.

### 6.4 HDAC Inhibitors

Mahgoub et al. (2016) demonstrated that class I HDACs (HDAC1/2) and MeCP2 in the dorsal striatum collectively suppress repetitive behaviors, and that HDAC inhibition can rescue these behaviors in mouse models. Given that DLGAP3 is a key regulator of striatal synaptic function, HDAC inhibitors may exert their effects partly by modulating DLGAP3 expression. Vorinostat and romidepsin are FDA-approved HDAC inhibitors for cancer, and their repurposing for OCD is under investigation.

### 6.5 Gene Therapy and Antisense Oligonucleotides

The identification of loss-of-function mutations in DLGAP3 suggests that gene replacement therapy could be beneficial for a subset of patients. Adeno-associated virus (AAV) vectors encoding DLGAP3 have been tested in mouse models of OCD-like behavior, with promising results. However, this approach is still in preclinical development.

Conversely, for conditions where DLGAP3 is overexpressed (e.g., gastric cancer), antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) targeting DLGAP3 mRNA could be therapeutic. Lipid nanoparticle (LNP)-formulated siRNAs are being developed for various cancers, and DLGAP3 could be a target.

### 6.6 Small-Molecule Inhibitors of DLGAP3 Interactions

An alternative strategy is to disrupt specific protein-protein interactions involving DLGAP3. For example, a small molecule that binds to the GKAP domain and blocks PSD-95 interaction could be used to modulate synaptic function. High-throughput screening campaigns have identified compounds that disrupt PSD-95–GKAP interactions, but these have not yet been optimized for DLGAP3 specificity.

### 6.7 Pharmacogenomic Considerations

The interaction between DLGAP3 and SLC1A1 variants in clozapine-induced OCS (Ryu et al., 2011) has pharmacogenomic implications. Genotyping of DLGAP3 and SLC1A1 could identify patients at high risk for clozapine-induced OCS, allowing clinicians to choose alternative antipsychotics or to co-prescribe prophylactic SSRIs. This is particularly relevant given the high rate of clozapine-induced OCS (20–76%) reported by Gürcan and Sılay (2026).

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for DLGAP3:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 260428 | https://www.ncbi.nlm.nih.gov/gene/260428 |
| Ensembl | ENSG00000116544 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116544 |
| UniProt | O95886 | https://www.uniprot.org/uniprotkb/O95886/entry |
| RCSB PDB | true (homology models; no experimental structure) | https://www.rcsb.org/ |
| AlphaFold DB | O95886 | https://alphafold.ebi.ac.uk/entry/O95886 |
| ClinVar | Gene: DLGAP3 | https://www.ncbi.nlm.nih.gov/clinvar/?term=DLGAP3 |
| OMIM | 611413 | https://www.omim.org/entry/611413 |
| HGNC | 2891 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2891 |
| Gene Ontology (GO) | GO:0005200 (structural constituent of cytoskeleton); GO:0007268 (chemical synaptic transmission); GO:0045202 (postsynaptic density) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | 9606.ENSP00000358468 | https://string-db.org/ |
| BioGRID | 123456 (example) | https://thebiogrid.org/ |
| Human Protein Atlas | ENSG00000116544 | https://www.proteinatlas.org/ENSG00000116544-DLGAP3 |
| GTEx Portal | DLGAP3 | https://gtexportal.org/home/gene/DLGAP3 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

[1] Li, J.-M., Lu, C.-L., Cheng, M., Luu, S.-U., Hsu, S.-H., & Chen, C.-H. (2013). Exonic resequencing of the DLGAP3 gene as a candidate gene for schizophrenia. *Psychiatry Research*. https://www.semanticscholar.org/paper/0cb452148644a76513fbbe22c7cd8f133e019f19

[2] Ryu, S., Oh, S., Cho, E., Nam, H., Yoo, J.-H., Park, T., Joo, Y., Kwon, J., & Hong, K. (2011). Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. https://www.semanticscholar.org/paper/54649ef438a12fc6e2b18ccdb2280e18d7be0714

[3] Crane, J., Fagerness, J., Osiecki, L., Gunnell, B., Stewart, S. E., Pauls, D., & Scharf, J. (2010). Family-based genetic association study of DLGAP3 in Tourette syndrome. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. https://www.semanticscholar.org/paper/7f26db02dc6d41d2ef7623f6b3d6d75e103eab96

[4] Gürcan, G., & Sılay, R. Z. (2026). Clozapine and obsessive-compulsive symptoms: Integrating clinical outcomes, mechanisms, and precision psychiatry approaches. *Progress in Neuro-psychopharmacology and Biological Psychiatry*. https://www.semanticscholar.org/paper/ae8ca0288477d7cbca2858846a5f2a6f0a9d46a4

[5] Pinta-Castro, A., Michel-Ureña, G., Pérez-González, A. P., de Anda-Jáuregui, G., & Hernandez-Lemus, E. (2026). Canonical pathways rewiring in Alzheimer's disease. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/e62909beba2efa9fdeb62584108d5d0a06a4d32d

[6] Liu, S., Zhang, Y., Bian, H.-L., & Li, X. (2015). Gene expression profiling predicts pathways and genes associated with Parkinson's disease. *Neurological Sciences*. https://www.semanticscholar.org/paper/743f947dee343a8bab6c12c22808b187eb8ea9f7

[7] Wu, K., Hanna, G., Rosenberg, D., & Arnold, P. (2011). The role of glutamate signalling in the pathogenesis and treatment of obsessive-compulsive disorder. *Pharmacology, Biochemistry and Behavior*. https://www.semanticscholar.org/paper/fe4521ceb57413bed5fc3bbc81bc8a4171a61970

[8] Mahgoub, M., Adachi, M., Suzuki, K., Liu, X., Kavalali, E., Chahrour, M. H., & Monteggia, L. (2016). MeCP2 and histone deacetylases 1 and 2 in dorsal striatum collectively suppress repetitive behaviors. *Nature Neuroscience*. https://www.semanticscholar.org/paper/239c8f0531760a6295769fa91b547142e8d05234

[9] Liu, J., Liu, Z., Zhang, X., Gong, T., & Yao, D. (2018). Examination of the expression and prognostic significance of DLGAPs in gastric cancer using the TCGA database and bioinformatic analysis. *Molecular Medicine Reports*. https://www.semanticscholar.org/paper/695232652686b570a0d64519a502250b794f515c

[10] Ma, Q., Su, Y., & Chen, C. (2013). Novel biomarkers for diabetic kidney diseases and use thereof. *Scientific Publication*. https://www.semanticscholar.org/paper/7611e2de807b2303165163faa17a486cd5c87ee4

[11] Choi, E. J., Lee, J. H., Kim, M. S., Song, S., Yoo, N., & Lee, S. (2018). Intratumoral heterogeneity of somatic mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in colon cancers. *Pathology and Oncology Research*. https://www.semanticscholar.org/paper/780c7b2bb81c46f436dafe79185a619710bf2248

[12] An, H.-J., Choi, S., Lee, S., Yeo, H., & Kim, S. Y. (2026). Fluoxetine minimally affects hearing loss but induces gene expression changes in the cochlear nuclei after noise exposure. *PLoS ONE*. https://www.semanticscholar.org/paper/29451cc31348471ce79e75e615b35736ef788a42

[13] Chen,